Australian Family Physician
Australian Family Physician


Volume 41, Issue 10, October 2012

Andrology Reproductive years and beyond

Eric Chung
Download article
Cite this article    BIBTEX    REFER    RIS

In recent years, significant advances have been made in our knowledge of the role of testosterone in male fertility and sexual function. In addition, new microsurgical techniques have improved outcomes in testicular biopsy for sperm retrieval, varicocoele treatment and vasectomy reversal.
This article provides an update on the assessment and treatment of male infertility, and the role of testosterone replacement therapy and erectile dysfunction.
The evaluation of male infertility requires comprehensive history taking and a focused examination. Investigations that help form the basis for important treatment decisions include semen analysis and hormone testing. Further specialist assessment may be required to determine the need for genetic testing.
There is increased evidence for the role of microsurgery in sperm retrieval, varicocelectomy and vasectomy reversal in men seeking paternity.
Testosterone plays a role in both spermatogenesis and sexual functioning in a man. While testosterone replacement therapy can restore erections in androgen deficient men and treat other conditions related to hypogonadism, it can also result in male infertility.

In recent years, significant advances in our knowledge of the role of testosterone in male infertility and sexual function have been made. This article provides a timely review of male infertility treatments, the role of testosterone replacement and erectile dysfunction.


Approximately 15% of couples are unable to conceive after 1 year of unprotected intercourse. A male factor is solely responsible for about 20% of these and contributory in another 30–40%.1,2 Male infertility can result from a range of conditions (Table 1), but in 30–40% of cases no causative factor can be found (idiopathic male infertility).

Table 1. Reasons for male infertility
  • Congenital factors – cryptorchism and testicular dysgenesis, congenital absence of vas deferens
  • Acquired urogenital abnormalities – obstruction, testicular torsion, testicular tumour
  • Urogenital infections, including sexually transmissible infections
  • Varicocele
  • Endocrine disturbances
  • Genetic abnormalities (eg. Klinefelter syndrome, cystic fibrosis)
  • Systemic diseases
  • Gonadal toxins, including medications, toxins, radiation, lifestyle factors
  • Idiopathic (30–40% of men)

Evaluation of male infertility

While it is acceptable to allow at least 1 year for a couple to try to conceive naturally, the evaluation of male infertility should be performed earlier if male infertility risk factors exist (eg. a history of bilateral cryptorchidism) or if concerns are raised by the couple about the man’s fertility.2 The evaluation of male infertility should begin with a thorough history of:

  • previous fertility
  • sexual history (sexual desire, erection and/or ejaculation dysfunction, intercourse)
  • developmental history
  • risk factors for testicular dysfunction
    • family history of cryptorchidism
    • previous surgery (genitourinary or pelvic)
    • genitourinary infection
    • gonadal toxin exposure (eg. pesticides, illicit drug use and chemotherapy).

Physical evaluation

Physical examination should focus on:

  • evaluation of secondary male sexual characteristics including hair distribution and the presence of breast enlargement
  • presence of surgical scars (abdominal, inguinal or genital)
  • penile examination, including the location of the urethral meatus
  • testicular examination – size based on orchidometer, shape and consistency, presence of vasa and epidymides, presence of a varicocele.

Digital rectal examination for cystic dilatation of seminal vesicles or prostatic cyst is required in some cases and may be best performed by a specialist in the area of infertility.


Basic investigations in a suspected infertile man should include two semen analysis samples, endocrine and, in some cases, genetic testing (Table 2).2–4 New World Health Organization semen analysis parameters are described in Table 3.3

The analysis of sperm DNA damage, as an indicator of sperm quality, remains experimental and controversial.4

Based on testicular examination and semen analysis, the azoospermic individual can be classified as having obstructive (usually absent/low volume) or nonobstructive (usually normal volume) azoospermia. Nonobstructive azoospermia is characterised by abnormal testicular histology. The presence of normal semen volume, fructose in semen and an alkaline pH indicates that seminal vesicles are present and localises the obstruction to a site proximal to the junction of the vas deferens and seminal vesicles. The presence of any mature sperm in the semen excludes the possibility of complete absence of spermatogenesis.

The initial endocrine evaluation should include serum testosterone, follicle stimulating hormone (FSH) and luteinising hormone (LH) levels. An FSH >7.6 IU/L and testicular length <4.5 cm predicts the presence of nonobstructive azoospermia (NOA), with greater than 89% probability in azoospermic men.5 Genetic screening for male infertility such as chromosomal karyotyping, Y chromosome microdeletion and cystic fibrosis transmembrane regulator (CFTR) gene mutation is indicated in specific cases only and should be organised by an in vitro fertilisation (IVF) specialist. Scrotal ultrasonography is indicated when physical examination of the scrotum is difficult or inadequate, or when a testicular mass is suspected. Urinary tract ultrasound should be offered to any man with unilateral or bilateral vasal agenesis to exclude coexisting renal anomalies. Transrectal ultrasound can diagnose ejaculatory duct obstruction or an obstructing Müllerian or ejaculatory cyst.

Table 2. Investigations in male infertility
Semen analysis
  • Minimum two samples
  • Perform at least 1 month apart
  • Abstain from sexual activity for 2–3 days before collection
  • Semen can be collected by masturbation or intercourse using a special sterile semen collection condom (nonspermicidal) or jar
  • If sperm collection takes place outside of the laboratory, the specimen should be kept at room or body temperature during transport to the laboratory
  • Sample examination within 1 hour of collection
Blood tests
  • Follicle stimulating hormone and testosterone levels
  • Chromosomal karyotyping, Y chromosome microdeletion and CFTR gene mutation in selected cases
  • Scrotal ultrasound if suspect varicocele
  • Renal tract ultrasound to exclude renal anomalies if congenital bilateral absence of vas deferens suspected
  • Transrectal ultrasound if ejaculatory duct obstruction is suspected
Table 3. WHO lower reference limits (5th centiles and their 95% confidence intervals) for semen characteristics3
ParameterLower reference limit
Semen volume (mL) 1.5 (1.4–1.7)
Total sperm number (106/ejaculate) 39 (33–46)
Sperm concentration (106/mL) 15 (12–16)
Total motility (PR+NR [nonprogressive motility], %) 40 (38–42)
Progressive motility (PR, %) 32 (31–34)
Vitality (live spermatozoa, %) 58 (55–63)
Sperm morphology (normal forms, %) 4 (3–4)
Other consensus threshold values
pH ≥7.2
Peroxidase positive leukocytes (106/mL) <1.0
Mixed antiglobulin reaction (MAR) test (motile spermatozoa with bound particles, %) <50
Immunobead test (motile spermatozoa with bound beads, %) <50
Seminal zinc (µmol/ejaculate) ≥2.4
Seminal fructose (µmol/ejaculate) ≥13
Seminal neutral glucosidase (µmol/ejaculate) ≥20

The role of microsurgery in male infertility

Since the introduction of intra-cytoplasmic sperm injection (ICSI), testicular biopsy is performed for therapeutic and diagnostic purposes. Results of a single random biopsy of one testis may not be indicative of the spermatogenic process in the remainder of that testis or the contralateral testis.6 Microdissection testicular exploration and sperm extraction (TESE) is a microscopic surgical sperm retrieval technique that allows for more testicular tissue preservation and has a higher rate of sperm retrieval than conventional testicular biopsy. This technique should be considered the gold standard for sperm retrieval irrespective of previous histology or previous unsuccessful surgery.7 Unfortunately, microdissection TESE is highly specialised, time consuming and requires the presence of a laboratory scientist for sperm preparation following sperm retrieval.

Varicocele – defined as abnormally dilated scrotal veins – is the commonest reversible male infertility factor.8 Significant evidence suggests that clinical varicocele has a harmful effect on the testis and that varicocelectomy can not only prevent progressive decline in testicular function but also reverse the damage. Recent meta-analysis concluded that microsurgical varicocelectomy is associated with significant improvement in all semen parameters (concentration, motility and morphology) and has the highest spontaneous pregnancy rates and lowest complication rates when compared to other modalities of varicocele treatment.9 Cost effectiveness analysis showed that primary treatment with varicocelectomy was more cost effective than sperm retrieval/ICSI.10 Even though spontaneous pregnancy remains the ultimate standard for evaluating the success of varicocele treatment, the improvements in semen parameters may allow for some couples to proceed with intrauterine insemination (IUI) before more advanced assisted reproductive technologies.11

Microsurgical vasectomy reversal is a cost effective, reliable and effective means of restoring fertility, and has been shown to have higher spontaneous pregnancy rates than ICSI/IVF when there are no other male or female infertility factors.12,13 Unfortunately, the current data comparing vasectomy reversal and sperm retrieval/ICSI/IVF are neither randomised nor homogenous12,13 and presently there is increased use of ICSI as opposed to microsurgical vasectomy reversal among many men seeking paternity. This could be due to a number of factors including lack of microsurgery expertise in some areas, misperception and reluctance for referral by some IVF gynaecologists, differential Medicare rebates for microsurgery, reluctance of men to undergo the surgery, increasing female age and the perceived urgency for conception using IVF.

Testosterone, male fertility and contraception

Testosterone is essential to maintain spermatogenesis and male fertility. However, exogenous testosterone suppresses the secretion of the pituitary gonadotropins, decreases endogenous testosterone secretion from the testis and deprives developing sperm of the signals required for normal maturation. This can result in a decline in sperm production and male infertility. Whether or not endogenous testosterone levels and/or spermatogenesis recover if exogenous testosterone use is ceased, remains uncertain.

Various male contraceptive regimens, either testosterone alone or in combination with a progestin, have been developed14 and studies show that after 2–3 months of treatment, low levels of pituitary gonadotropins lead to markedly decreased sperm counts and effective contraception in the majority of men.15 While these novel contraceptive methods for men show promise, there are currently no commercially available male hormonal contraceptives due to variable efficacy and poor side effect profiles.

Erectile dysfunction and male hypogonadism

Erectile dysfunction (ED), low testosterone levels and metabolic and cardiovascular disease are recognised as being closely linked16 and a clear negative relationship exists between the presence of risk factors for metabolic syndrome and levels of circulating testosterone in patients with ED.16,17 The current literature indicates that testosterone controls (either directly or indirectly) several mechanisms that lead to penile erection. These include promoting the commitment of penile stem cells to a smooth muscle phenotype and regulation of the formation of nitric oxide and expression of phosphodiesterase type 5.17

Male hypogonadism is defined as the failure to maintain adequate testosterone levels and/or sperm production. The diagnosis of primary and secondary hypogonadism is based on the levels of gonadotropins (LH and FSH), testosterone and/or sperm levels. Studies have shown that hypogonadal men restored to the eugonadal state with testosterone replacement therapy (TRT) may experience a general improvement in sexual function (particularly ejaculation, orgasm and penile sensations) improved erections and restored or enhanced responsiveness to PDE5 inhibitors.18 The last is an important indication for TRT, especially in men with type 2 diabetes, where the response to PDE5 inhibitors alone may be little more than 50%.19 When choosing which TRT to prescribe, the physician must exercise good clinical judgement together with adequate knowledge of the advantages and drawbacks of TRT and consider the bioavailability, safety, tolerability and efficacy of each TRT product as well as any contraindications to TRT. Regular patient follow up is important following TRT initiation. Adverse events during therapy, such as an elevated hematocrit or prostate specific antigen (PSA), require rapid discontinuation of TRT and, as such, short acting preparations are preferred over long acting depot preparations in the initial treatment of hypogonadal men. Primary care physicians may wish to refer these patients to a specialist experienced in the area.

At present, the use of gonadotrophic hormones such as human chorionic gonadotropin and selective oestrogen receptor modulators (eg. clomiphene citrate) is not recommended in male hypogonadism except when fertility is an issue.20,21


The evaluation of male infertility requires semen analysis, endocrine testing and in some cases, genetic testing. There is increased evidence for the role of microsurgery in both sperm retrieval and varicocelectomy.

While testosterone replacement therapy restores erection in androgen deficient men and treats other hypogonadism related conditions, it can result in male infertility.

Key points

  • The evaluation of male infertility requires comprehensive history taking, focused examination, semen analysis and hormone testing.
  • Genetic testing for male infertility such as chromosomal karyotyping, Y chromosome microdeletion and CFTR gene mutation should be organised by an IVF specialist.
  • Microsurgical sperm retrieval and varicocelectomy are state-of-the-art care for the infertile male.
  • Microsurgical vasectomy reversal is more cost effective than ICSI/IVF.
  • Exercise caution in the use of testosterone replacement therapy in younger men due to the risk of infertility.

Conflict of interest: Eric Chung has received payment from Lilly, GlaxoSmithKline and AMS for consultancy, lectures and travel.

  1. Meacham RB, Joyce GF, Wise M, et al. Male infertility. J Urol 2007;177:2058–66. Search PubMed
  2. Gangel EK, American Urological Association, Inc and American Society for Reproductive Medicine. AUA and ASRM produce recommendations for male infertility. American Urological Association, Inc and American Society for Reproductive Medicine. Am Fam Physician 2002;65:2589–90. Search PubMed
  3. World Health Organization. WHO Laboratory Manual for Examination and Processing of Human Semen. 5th edn. Geneva: WHO, 2010. Search PubMed
  4. Avendano C, Franchi A, Duran H, Oehninger S. DNA fragmentation of normal spermatozoa negatively impacts embryo quality and intracytoplasmic sperm injection outcome. Fertil Steril 2010;94:549–57. Search PubMed
  5. Schoor RA, Eklhamby S, Niederberger CS, Ross LS. The role of testicular biopsy in the modern management of male infertility. J Urol 2002;167:197–200. Search PubMed
  6. Kalsi J, Thurn MY, Muneer A, Abdullah H, Minhas S. In the era of micro-dissection sperm retrieval (m-TESE) is an isolated testicular biopsy necessary in the management of men with non-obstructive azoospermia? BJU Int 2012;109:418–24. Search PubMed
  7. The Practice Committee of the American Society for Reproductive Medicine. Sperm retrieval for obstructive azoospermia. Fertil Steril 2008;90:S213–8. Search PubMed
  8. Cocuzza M, Cocuzza MA, Bragais FMP, Agarwal A. The role of varicocele repair in the new era of assisted reproductive technology. Clinics 2008;63:395–404. Search PubMed
  9. Cayan S, Sharakhabov S, Kadioglu A. Treatment of palpable varicocele in infertile men: a meta-analysis to define the best technique. J Androl 2009;30:33–40. Search PubMed
  10. Meng MV, Greene KL, Turek PJ. Surgery or assisted reproductive? A decision analysis of treatment costs in male infertility. J Urol 2005;174:1926–31, discussion 31. Search PubMed
  11. Abdel-Meguid T, Al-Sayyad A, Tayib A, Farsi HM. Does varicocele repair improve male infertility? An evidence-based perspective from a randomized, controlled trial. Eur Urol 2011;59:455–61. Search PubMed
  12. Shridharani A, Sandlow JI. Vasectomy reversal versus IVR with sperm retrieval: which is better? Curr Opin Urol 2010;20:503–9. Search PubMed
  13. Lee R, Li PS, Goldstein M, Tanrikut C, Schattman G, Schlegel PN. A decision analysis of treatments for obstructive azoospermia. Hum Reprod 2008;23:2043–9. Search PubMed
  14. Nieschlag E. The struggle for male hormonal contraception. Best Pract Res Clin Endocrinol Metab 2011;25:369–75. Search PubMed
  15. Wu FCW. Hormonal approaches to male contraception: approaching reality. Mol Cell Endocrinol 2006;250:2–7. Search PubMed
  16. Corona G, Monami M, Rastrelli G, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med 2011;8:272–83. Search PubMed
  17. Corona C, Maggi M. The role of testosterone in erectile dysfunction. Nat Rev Urol 2010;7:46–56. Search PubMed
  18. Bolona ER, Uraga MV, Haddad RM, et al. Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007:82:20–8. Search PubMed
  19. Wang C, Nieschlag E, Swerdloff R, et al. Investigation, Treatment, and Monitoring of Late-Onset Hypogonadism in Males: ISA, ISSAM, EAU, EAA, and ASA Recommendations. Eur Urol 2009;55:121–30. Search PubMed
  20. Petak SM, Nankin HR, Spark RF, et al. The American Society for Reproductive Medicine, Birmingham, Alabama. Androgen deficiency in the aging male. Fertil Steril 2008;90:S83–7. Search PubMed
  21. Corona G, Rastrelli G, Vignozzi L, Maggi M. Emerging medication for the treatment of male hypogonadism. Expert Opin Emerg Drugs 2012;17:239–59. Search PubMed
Download article PDF


Australian Family Physician RACGP

Printed from Australian Family Physician - https://www.racgp.org.au/afp/2012/october/andrology
© The Australian College of General Practitioners www.racgp.org.au